Options for efficient regulation of the UK pharmaceutical market

Fil: Ferraro, Jimena. Universidad de San Andrés. Departamento de Economía; Argentina.

Detalles Bibliográficos
Autor principal: Ferraro, Jimena
Otros Autores: Towse, Adrian
Formato: Tesis Tesis de maestría updatedVersion
Lenguaje:Inglés
Publicado: Universidad de San Andrés. Departamento de Economía 8/18
Acceso en línea:http://hdl.handle.net/10908/18504
Aporte de:
id I37-R143-10908-18504
record_format dspace
spelling I37-R143-10908-185042025-01-29T16:35:41Z Options for efficient regulation of the UK pharmaceutical market Ferraro, Jimena Towse, Adrian Mestre Ferrandiz, Jorge Fil: Ferraro, Jimena. Universidad de San Andrés. Departamento de Economía; Argentina. The pharmaceutical industry is subject to economic regulation by governments almost all over the globe. In the UK, the pharmaceutical industry has been subject to the Pharmaceutical Price Regulation Scheme (PPRS) to sell branded medicines to the National Health Service (NHS) since 1978. The PPRS has, in the past, comprised of a combination of price and profit control. However, since 2014, the PPRS has, for the first time as the main regulatory mechanism, an aggregate revenue growth rate cap for branded medicines sold to the NHS. This last change was a new measure to limit the increasing burden of the medicines procurement costs, and it triggered questioning about the current way the industry is regulated. In line with this, in this paper, we review other options for the pharmaceutical industry's future regulation in the UK, setting out options that seem to be worth considering. With this purpose, we summarise pharmaceutical regulation in five other OECD countries, identifying options that may be relevant to the UK. Then, we review the UK utility sector's experience of economic regulation identifying options that may apply to the UK pharmaceutical industry. Finally, we discuss options for the future of the UK pharmaceutical industry and issues to be addressed. We consider each option the potential for reducing any duplication of regulatory instruments and a general reduction in the burden of regulation. 8/18/2021 17:53Z 8/18/2021 17:53Z 2021-03 Tesis info:eu-repo/semantics/masterThesis info:ar-repo/semantics/tesis de maestría info:eu-repo/semantics/updatedVersion Ferraro, J. (2021). Options for efficient regulation of the UK pharmaceutical market. [Tesis de maestría, Universidad de San Andrés. Departamento de Economía]. Repositorio Digital San Andrés. http://hdl.handle.net/10908/18504 http://hdl.handle.net/10908/18504 eng info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf application/pdf Universidad de San Andrés. Departamento de Economía
institution Universidad de San Andrés
institution_str I-37
repository_str R-143
collection Repositorio Digital - Universidad de San Andrés (UdeSa)
language Inglés
description Fil: Ferraro, Jimena. Universidad de San Andrés. Departamento de Economía; Argentina.
author2 Towse, Adrian
author_facet Towse, Adrian
Ferraro, Jimena
format Tesis
Tesis de maestría
Tesis de maestría
updatedVersion
author Ferraro, Jimena
spellingShingle Ferraro, Jimena
Options for efficient regulation of the UK pharmaceutical market
author_sort Ferraro, Jimena
title Options for efficient regulation of the UK pharmaceutical market
title_short Options for efficient regulation of the UK pharmaceutical market
title_full Options for efficient regulation of the UK pharmaceutical market
title_fullStr Options for efficient regulation of the UK pharmaceutical market
title_full_unstemmed Options for efficient regulation of the UK pharmaceutical market
title_sort options for efficient regulation of the uk pharmaceutical market
publisher Universidad de San Andrés. Departamento de Economía
publishDate 8/18
url http://hdl.handle.net/10908/18504
work_keys_str_mv AT ferrarojimena optionsforefficientregulationoftheukpharmaceuticalmarket
_version_ 1824439023609839616